Stone Ian S, John Leonette, Petersen Steffen E, Barnes Neil C
Department of Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London E2 9JX, UK; Centre for Advanced Cardiovascular Imaging, William Harvey Research Institute, NIHR Cardiovascular Biomedical Research Unit at Barts, The London Chest Hospital, London E2 9JX, UK.
Respir Med. 2013 Nov;107(11):1700-8. doi: 10.1016/j.rmed.2013.06.008. Epub 2013 Aug 3.
Significant cardiovascular morbidity and mortality exists in chronic obstructive pulmonary disease (COPD). Arterial stiffness is raised in COPD and may be a mechanistic link. Non-invasive assessment of arterial stiffness has the potential to be a surrogate outcome measure, although no reproducibility data exists in COPD patients. Two studies (23 and 33 COPD patients) were undertaken to 1) assess the Vicorder reproducibility of carotid-femoral pulse wave velocity and Augmentation index in COPD; 2) compare it to SphygmoCor; and 3) assess the contribution of lung hyperinflation to measurement variability. There were excellent correlations and good agreement between repeat Vicorder measurements for carotid-femoral pulse wave velocity (r = 0.96 (p < 0.001); mean difference ±SD = -0.03 ± 0.36 m/s (p = 0.65); co-efficient of reproducibility = 4.02%; limits of agreement = -0.68-0.75 m/s). Augmentation index significantly correlated (r = 0.736 (p < 0.001); mean difference ±SD = 0.72 ± 4.86% (p = 0.48), however limits of agreement were only 10.42-9.02%, with co-efficient of reproducibility of 27.93%. Comparing devices, Vicorder values were lower but there was satisfactory agreement. There were no correlation between lung hyperinflation (as measured by residual volume percent predicted, total lung capacity percent predicted or the ratio of inspiratory capacity to residual volume) and variability of measurements in either study. In COPD, measurement of carotid-femoral pulse wave velocity is highly reproducible, not affected by lung hyperinflation and suitable as a surrogate endpoint in research studies. Day-to-day variation in augmentation index highlights the importance of such studies prior to the planning and undertaking of clinical COPD research.
慢性阻塞性肺疾病(COPD)存在显著的心血管发病率和死亡率。COPD患者的动脉僵硬度升高,这可能是一个机制性联系。尽管COPD患者中尚无重复性数据,但动脉僵硬度的非侵入性评估有可能成为替代结局指标。开展了两项研究(分别有23例和33例COPD患者),以1)评估Vicorder在COPD患者中测量颈股脉搏波速度和增强指数的重复性;2)将其与SphygmoCor进行比较;3)评估肺过度充气对测量变异性的影响。颈股脉搏波速度的重复Vicorder测量之间存在极好的相关性和良好的一致性(r = 0.96(p < 0.001);平均差值±标准差=-0.03±0.36 m/s(p = 0.65);重复性系数= 4.02%;一致性界限=-0.68 - 0.75 m/s)。增强指数显著相关(r = 0.736(p < 0.001);平均差值±标准差= 0.72±4.86%(p = 0.48)),然而一致性界限仅为10.42 - 9.02%,重复性系数为27.93%。比较不同设备时,Vicorder的值较低,但一致性令人满意。在两项研究中,肺过度充气(通过预测残气量百分比、预测肺总量百分比或吸气量与残气量之比测量)与测量变异性之间均无相关性。在COPD中,颈股脉搏波速度的测量具有高度重复性,不受肺过度充气影响,适合作为研究中的替代终点。增强指数的日常变化凸显了在规划和开展COPD临床研究之前进行此类研究的重要性。